University College London

Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, June 29, 2022
Bristol Myers Squibb, Patient, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hypoparathyroidism, Physiology, GLOBE, Acromegaly, FRCS, Royal College of Surgeons, Endocrinology, Food, NHS, Therapy, Clinical trial, Degenerative disease, PTH, Royal college, Twitter, University College London, Fine chemical, Pharmaceutical industry, EU

Dr. Sumeray joins Amolyt from Amryt Pharmaceuticals, where he served as chief medical officer since September 2016.

Key Points: 
  • Dr. Sumeray joins Amolyt from Amryt Pharmaceuticals, where he served as chief medical officer since September 2016.
  • We are very pleased to have Mark join our team, said Thierry Abribat, Ph.D., founder, and chief executive officer of Amolyt Pharma.
  • Prior to joining Amolyt, he spent six years as chief medical officer at Amryt Pharmaceuticals where he supervised the development, regulatory and safety departments of the company.
  • Prior to Amryt, Dr. Sumeray served as chief medical officer at Aegerion Pharmaceuticals and earlier in his career, he led the US cardiovascular and metabolic medical affairs team at Bristol-Myers Squibb.

meQuilibrium Appoints Experience Design Expert Dustin DiTommaso as Chief Design Officer

Retrieved on: 
Thursday, June 23, 2022
United States Environmental Protection Agency, Industry, Center, Cleveland Clinic, Bill, Science, University College London, Technology, Neuroscience, Rhode Island School of Design, CEO, MEQ, Research, Berklee College of Music, National Information and Communication Technology Awards, Ghana Environmental Protection Agency, Workforce, Financial Times, Bill & Melinda Gates Foundation, AARP, AI, Organization, Management, Humana, Music

BOSTON, June 23, 2022 /PRNewswire/ -- meQuilibrium, the leading digital workforce resilience solution, has announced that renowned experience design expert Dustin DiTommaso has joined the executive team as Chief Design Officer.

Key Points: 
  • BOSTON, June 23, 2022 /PRNewswire/ -- meQuilibrium, the leading digital workforce resilience solution, has announced that renowned experience design expert Dustin DiTommaso has joined the executive team as Chief Design Officer.
  • Reporting directly to CEO Jan Bruce, Dustin will have lead responsibility for the look, feel, design and impact of the meQuilibrium platform, focusing on advancements in the member experience, behavior change and engagement.
  • Dustin joins meQuilibrium from the strategic design agency, Mad*Pow, where he founded the behavior change design practice, served as SVP Behavior Change Design and worked to integrate behavioral and social science, design and technology to create products, services, and programs that change real-world behaviors and improve the human condition.
  • "We are thrilled to welcome Dustin to the meQ team," said Jan Bruce, CEO and co-founder, meQuilibrium.

Greengates School in Mexico joins Nord Anglia Education's global family of schools

Retrieved on: 
Wednesday, June 22, 2022
Student, Primary school, Education, Imperial College London, IB Diploma Programme, University College London, King's College London, School, International education, MIT, St Patrick's College, London, Brown University, University of Maryland Global Campus, IGCSE, UNICEF, Greengates School, University of California, Berkeley, University, Juilliard School, Stanford University, IPC, Secondary school, Priscilla, International Baccalaureate, Nord Anglia International School Dubai, International, London School of Economics, Tutoring, Economics, Nord Anglia Education, Greengates

LONDON, June 22, 2022 /PRNewswire/ --Leading premium international schools organisation Nord Anglia Education today announced that Greengates School has become part of its global family of schools.

Key Points: 
  • LONDON, June 22, 2022 /PRNewswire/ --Leading premium international schools organisation Nord Anglia Education today announced that Greengates School has become part of its global family of schools.
  • Founded in 1951, Greengates is Nord Anglia's third school in Mexico and its 78th school worldwide.
  • Greengates is a leading British international school in Mexico, teaching more than 1,000 K-12 students with lessons in English and Spanish.
  • Andrew Fitzmaurice, Chief Executive Officer of Nord Anglia Education, said: "We're delighted that Greengates is joining our global family of schools.

Greengates School in Mexico joins Nord Anglia Education's global family of schools

Retrieved on: 
Wednesday, June 22, 2022
Student, Primary school, Education, Imperial College London, IB Diploma Programme, University College London, King's College London, School, International education, MIT, St Patrick's College, London, Brown University, University of Maryland Global Campus, IGCSE, UNICEF, Greengates School, University of California, Berkeley, University, Juilliard School, Stanford University, IPC, Secondary school, Priscilla, International Baccalaureate, Nord Anglia International School Dubai, International, London School of Economics, Tutoring, Economics, Nord Anglia Education, Greengates

LONDON, June 22, 2022 /PRNewswire/ --Leading premium international schools organisation Nord Anglia Education today announced that Greengates School has become part of its global family of schools.

Key Points: 
  • LONDON, June 22, 2022 /PRNewswire/ --Leading premium international schools organisation Nord Anglia Education today announced that Greengates School has become part of its global family of schools.
  • Founded in 1951, Greengates is Nord Anglia's third school in Mexico and its 78th school worldwide.
  • Greengates is a leading British international school in Mexico, teaching more than 1,000 K-12 students with lessons in English and Spanish.
  • Andrew Fitzmaurice, Chief Executive Officer of Nord Anglia Education, said: "We're delighted that Greengates is joining our global family of schools.

Discreet Labs Announces Warren Paul Anderson as CEO and Weikeng Chen as Chief Scientist

Retrieved on: 
Wednesday, June 22, 2022
Zero, Knowledge, XRP, Bitcoin, Ethereum, Doctor of Philosophy, Privacy, Contract, Industry, SRS, Blockchain, University College London, PALO, Technology, ZKP, CEO, UC, OTC, ZKP RTVS, Security, Science and technology in Asia, Research, Decentralized finance, University of Zurich, Prism, DAPP, MPC, Ecosystem, CPU, University, Harvard University, EVM, Yellow Submarine, Marlin, Ripple (payment protocol), Partnership, Warren, UTXO, Stanford University, VP, University of California, Berkeley, ACM, Cryptocurrency, Ripple, Northwestern

PALO ALTO, Calif., June 22, 2022 /PRNewswire-PRWeb/ -- Discreet Labs is proud to announce the promotion of Warren Paul Anderson into the role of CEO. Previously, Warren held the title of VP of Product at Discreet Labs where he has proven instrumental in helping to develop and launch many technical milestones over the past year on Findora, a high-performance EVM-compatible public blockchain utilizing Zero-Knowledge Proofs (ZKP) to bring privacy to Web3.

Key Points: 
  • PALO ALTO, Calif., June 22, 2022 /PRNewswire-PRWeb/ -- Discreet Labs is proud to announce the promotion of Warren Paul Anderson into the role of CEO.
  • Dr. Weikeng (pronounced "waken") Chen has also joined Discreet Labs as Chief Scientist where he will be leading cryptography research and development.
  • Weikeng is among a small group of cryptographers that have dedicated their academic careers to the technologies that Discreet Labs is building to scale web3 privacy.
  • We are proud to welcome Warren as CEO and Weikeng as Chief Scientist of Discreet Labs and look forward to the future innovation they will drive forward for Findora and more.

Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline

Retrieved on: 
Tuesday, June 21, 2022
Research, Finance, Genetics, Clinical Trials, Professional Services, Biotechnology, Health, Other Science, Science, Yan, Beverly Davidson, Partner, MBBS, University, Director, LinkedIn, Pressure, CFTR, Vertex, Inflammation, National Institute of Dental and Craniofacial Research, Therapy, Company, University College London, Tissue, AAV, Technology, CEO, University of Iowa, MRCP, Founder, Lung, Alnylam Pharmaceuticals, Board, University of Kansas, Parvoviridae, Industry, Tropism, UCL Great Ormond Street Institute of Child Health, Chairperson, FRCP, List of life sciences, Lists of diseases, Patient, Multimedia, Cystic fibrosis, Senior, CBO, Cystic Fibrosis Foundation, Gene, Research, Program, Infection, Doctor of Philosophy, UCL, Center, Roy J. and Lucille A. Carver College of Medicine, Pharmaceutical industry, Management, Pediatric nursing, Photis Kontoglou, Molecular medicine, Engelhardt, Microbiology

Carbon Biosciences (Carbon), a Longwood Fund founded biotech company and emerging leader in the development of novel parvovirus-derived gene therapies, today announced a $38 million Series A financing led by Agent Capital.

Key Points: 
  • Carbon Biosciences (Carbon), a Longwood Fund founded biotech company and emerging leader in the development of novel parvovirus-derived gene therapies, today announced a $38 million Series A financing led by Agent Capital.
  • Carbon is harnessing novel parvovirus vectors that can deliver larger gene therapy payloads with enhanced tissue specificity and with minimal neutralizing immunity.
  • Carbons technology will enable a diversified pipeline with potential applications across the wide range of tissues impacted in many unaddressed diseases.
  • Carbons scientific co-founders and scientific advisory board members are among the most experienced thought leaders in the gene therapy field.

The Mark Foundation for Cancer Research Awards ~$12 million to Cancer Grand Challenges Team Developing Novel Immunotherapies for Childhood Solid Tumors

Retrieved on: 
Thursday, June 16, 2022
Doctor of Philosophy, Survivor, Association, Extrachromosomal circular DNA, Therapy, University College London, Cachexia, Harvard Medical School, Tissue, Biology, Sarcoma, CAR, Cone Health Women's Hospital, Research, Children's National Hospital, National, AECC, Child, Disease, Cancer research, Drug discovery, MD, Lymphatic system, Prognosis, Program, Investment, Neoplasm, Hospital, Partnership, Death, Nextgen, Cancer Research UK, Patient, Financial toxicity, Diagnosis, Brain, Geography, National Cancer Institute, Vaccine, Pharmaceutical industry, Dietary supplement, Medicine, Genetics, Cancer, Brigham

NEW YORK, June 16, 2022 /PRNewswire/ -- The Mark Foundation for Cancer Research today announces a new ~$12 million grant to support a global team developing novel immunotherapies for children with solid tumors through Cancer Grand Challenges, an international funding initiative aiming to answer some of the biggest questions facing cancer research worldwide. With this award, the NexTGen team, led by Professor Catherine Bollard (Children's National Hospital, US) and Dr. Martin Pule (University College London, UK), seeks to build a deeper understanding of childhood brain tumors and sarcomas, leading to the development of effective CAR T-cell therapy treatments for these patients.

Key Points: 
  • NEW YORK, June 16, 2022 /PRNewswire/ -- The Mark Foundation for Cancer Research today announces a new ~$12 milliongrant to support a global team developing novel immunotherapies for children with solid tumors through Cancer Grand Challenges , an international funding initiative aiming to answer some of the biggest questions facing cancer research worldwide.
  • Cancer Grand Challenges sought to address this unmet need by issuing the Solid Tumors in Children Challenge, which tasks researchers with developing novel therapies that take into account the unique biology of childhood tumors.
  • "We're delighted that The Mark Foundation for Cancer Research has partnered with Cancer Grand Challenges to co-fund the team taking on our Solid Tumors in Children Challenge," says David Scott, PhD, Director of Cancer Grand Challenges, Cancer Research UK.
  • In 2022, The Mark Foundation received an additional $500 million commitment to fund cutting-edge cancer research in its first decade.

Cancer Grand Challenges Celebrates New Teams Joining World-Class Scientific Community

Retrieved on: 
Thursday, June 16, 2022
Research, Genetics, Stem Cells, Philanthropy, Biotechnology, Health, Fund Raising, Science, Oncology, Time, Heart, Freedom, University College London, Cachexia, CRUK, Tumor microenvironment, Institute, Sarcoma, University of California, Research, Nursing, Knowledge, Weill Cornell Medicine, Rutgers Cancer Institute of New Jersey, Stanford University School of Medicine, National, Grand Challenges, Â, Disease, DNA, University, Eppley Institute for Research in Cancer and Allied Diseases, Health, Cold Spring Harbor Laboratory, Quality of life, Rolling circle replication, Development, International Agency for Research on Cancer, Survival, Organic, NCI, Cancer Research UK, Patient, Neoplasm, Thought, Diagnosis, Cell, Brain, Geography, National Cancer Institute, Pharmaceutical industry, Dietary supplement, Medical imaging, Renewable energy, Cancer

At its core, Cancer Grand Challenges provides multidisciplinary teams the time, space and freedom to innovate and drive progress against cancer that the world urgently needs.

Key Points: 
  • At its core, Cancer Grand Challenges provides multidisciplinary teams the time, space and freedom to innovate and drive progress against cancer that the world urgently needs.
  • Along with its founding partners, the National Cancer Institute and Cancer Research UK, Cancer Grand Challenges leverages support from partners across the globe who share the same vision to fuel scientific discovery through collaboration.
  • The four new Cancer Grand Challenges teams add to a growing community of investigators daring to take on cancers toughest challenges now 700+ researchers, advocates and partners across 10 countries and 68 research institutions.
  • Co-founded in 2020 by two of the largest funders of cancer research in the world, Cancer Research UK and the National Cancer Institute, Cancer Grand Challenges supports a global community of diverse, world-class research teams to come together, think differently and take on some of cancers toughest challenges.

Lenire Biosciences Completes License Agreement with University College London for VSN16R, A Novel Clinical Candidate Treatment for Fragile X Syndrome

Retrieved on: 
Thursday, June 16, 2022
Multiple sclerosis, Myalgia, Spasticity, Patent, Therapy, Attention deficit hyperactivity disorder predominantly inattentive, Attention, Learning, 2009 Davis Cup, University College London, Anxiety, Residential treatment center, Technology, Cincinnati, Attention deficit, Company, Cincinnati Children's Hospital Medical Center, Human, Research, BK, Professor, Autism, UCL Business, Psychiatry, Intellectual disability, Patient, Biomedical Research, UCL, Attention deficit hyperactivity disorder, Disorder, SAN, FXS, Fragile X syndrome, GLOBE, Prevalence, Syndrome, Pharmaceutical industry

The development of this technology was supported by UCL Business (UCLB), the commercialization company of UCL.

Key Points: 
  • The development of this technology was supported by UCL Business (UCLB), the commercialization company of UCL.
  • FXS is a rare, inherited condition that can cause issues including developmental delays, learning and behavioural difficulties, physical abnormalities, anxiety, attention or hyperactivity disorders and autism spectrum disorder.
  • FXS is the most prevalent inherited form of intellectual disability and a leading cause of autism spectrum disorder.
  • Lenire Biosciences is privately held, clinical stage biopharmaceutical company that is developing novel, patent protected therapeutics for the treatment of Fragile X Syndrome (FXS), a leading cause of intellectual disability world-wide that also presents with anxiety, attention deficit, hyperactivity, autism spectrum behaviors and other disabling symptoms.

Children’s National Hospital Catherine Bollard selected to lead global Cancer Grand Challenges team taking on solid tumors in children

Retrieved on: 
Thursday, June 16, 2022
Survival, CAR, Stanford University School of Medicine, Cardiff University, Rhabdomyosarcoma, Disease, National, Hospital, Death, Cancer Research UK, U.S. News & World Report, Geography, GLOBE, National Cancer Institute, Time, Survivor, Immunology, Nursing, University College London, CEO, News, Degenerative disease, Grand Challenges, Stanford University, Program, No, Children's National Hospital, University college, Hope, Biostatistics, Institute, Good manufacturing practice, Lymphatic system, Harwell Science and Innovation Campus, Nextgen, Financial toxicity, Health, Mathematics, Human, Research, Proteomics, Center, Mobile phone, Vaccine, Pharmaceutical industry, Dietary supplement, Child, Cancer, INSERM, D.C

, director of the Center for Cancer and Immunology Research at Childrens National Hospital, has been selected to receive a $25m Cancer Grand Challenges award to tackle solid tumors in children.

Key Points: 
  • , director of the Center for Cancer and Immunology Research at Childrens National Hospital, has been selected to receive a $25m Cancer Grand Challenges award to tackle solid tumors in children.
  • With our Cancer Grand Challenge, we hope to bring next-generation CAR T-cell therapies to children with solid tumors, said Dr. Bollard.
  • The Cancer Grand Challenges NexTGen team, announced June 16, 2022, is taking on the initiatives Solid Tumours in Children challenge.
  • The Cancer Grand Challenges NexTGen team is funded by Cancer Research UK, the National Cancer Institute in the U.S. and The Mark Foundation for Cancer Research.